List of Tables
Table 1. Global Gene Editing Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Gene Editing Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Gene Editing Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Gene Editing Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Gene Editing Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Gene Editing Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Gene Editing Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Gene Editing Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Editing Therapy as of 2024)
Table 11. Global Gene Editing Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Gene Editing Therapy Companies Headquarters
Table 13. Global Gene Editing Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Gene Editing Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Gene Editing Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Gene Editing Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Gene Editing Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Gene Editing Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Gene Editing Therapy Growth Accelerators and Market Barriers
Table 25. North America Gene Editing Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Gene Editing Therapy Growth Accelerators and Market Barriers
Table 27. Europe Gene Editing Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Gene Editing Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Gene Editing Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Gene Editing Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Gene Editing Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Gene Editing Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Gene Editing Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. CRISPR Therapeutics Corporation Information
Table 35. CRISPR Therapeutics Description and Major Businesses
Table 36. CRISPR Therapeutics Product Features and Attributes
Table 37. CRISPR Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. CRISPR Therapeutics Revenue Proportion by Product in 2024
Table 39. CRISPR Therapeutics Revenue Proportion by Application in 2024
Table 40. CRISPR Therapeutics Revenue Proportion by Geographic Area in 2024
Table 41. CRISPR Therapeutics Gene Editing Therapy SWOT Analysis
Table 42. CRISPR Therapeutics Recent Developments
Table 43. Beam Therapeutics Corporation Information
Table 44. Beam Therapeutics Description and Major Businesses
Table 45. Beam Therapeutics Product Features and Attributes
Table 46. Beam Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Beam Therapeutics Revenue Proportion by Product in 2024
Table 48. Beam Therapeutics Revenue Proportion by Application in 2024
Table 49. Beam Therapeutics Revenue Proportion by Geographic Area in 2024
Table 50. Beam Therapeutics Gene Editing Therapy SWOT Analysis
Table 51. Beam Therapeutics Recent Developments
Table 52. Editas Medicine Corporation Information
Table 53. Editas Medicine Description and Major Businesses
Table 54. Editas Medicine Product Features and Attributes
Table 55. Editas Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Editas Medicine Revenue Proportion by Product in 2024
Table 57. Editas Medicine Revenue Proportion by Application in 2024
Table 58. Editas Medicine Revenue Proportion by Geographic Area in 2024
Table 59. Editas Medicine Gene Editing Therapy SWOT Analysis
Table 60. Editas Medicine Recent Developments
Table 61. Verve Therapeutics Corporation Information
Table 62. Verve Therapeutics Description and Major Businesses
Table 63. Verve Therapeutics Product Features and Attributes
Table 64. Verve Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Verve Therapeutics Revenue Proportion by Product in 2024
Table 66. Verve Therapeutics Revenue Proportion by Application in 2024
Table 67. Verve Therapeutics Revenue Proportion by Geographic Area in 2024
Table 68. Verve Therapeutics Gene Editing Therapy SWOT Analysis
Table 69. Verve Therapeutics Recent Developments
Table 70. Bluebird Bio Corporation Information
Table 71. Bluebird Bio Description and Major Businesses
Table 72. Bluebird Bio Product Features and Attributes
Table 73. Bluebird Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Bluebird Bio Revenue Proportion by Product in 2024
Table 75. Bluebird Bio Revenue Proportion by Application in 2024
Table 76. Bluebird Bio Revenue Proportion by Geographic Area in 2024
Table 77. Bluebird Bio Gene Editing Therapy SWOT Analysis
Table 78. Bluebird Bio Recent Developments
Table 79. Intellia Therapeutics Corporation Information
Table 80. Intellia Therapeutics Description and Major Businesses
Table 81. Intellia Therapeutics Product Features and Attributes
Table 82. Intellia Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Intellia Therapeutics Recent Developments
Table 84. Vertex Pharmaceuticals Corporation Information
Table 85. Vertex Pharmaceuticals Description and Major Businesses
Table 86. Vertex Pharmaceuticals Product Features and Attributes
Table 87. Vertex Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Vertex Pharmaceuticals Recent Developments
Table 89. Caribou Biosciences Corporation Information
Table 90. Caribou Biosciences Description and Major Businesses
Table 91. Caribou Biosciences Product Features and Attributes
Table 92. Caribou Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Caribou Biosciences Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Editing Therapy Product Picture
Figure 2. Global Gene Editing Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. In Vivo Gene Editing Product Picture
Figure 4. In Vitro Gene Editing Product Picture
Figure 5. Global Gene Editing Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Thalassemia
Figure 7. Cancer
Figure 8. Cystic Fibrosis
Figure 9. Muscular Dystrophy
Figure 10. Others
Figure 11. Gene Editing Therapy Report Years Considered
Figure 12. Global Gene Editing Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 14. Global Gene Editing Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Gene Editing Therapy Revenue Market Share by Region (2020-2031)
Figure 16. Global Gene Editing Therapy Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. In Vivo Gene Editing Revenue Market Share by Player in 2024
Figure 19. In Vitro Gene Editing Revenue Market Share by Player in 2024
Figure 20. Global Gene Editing Therapy Revenue Market Share by Type (2020-2031)
Figure 21. Global Gene Editing Therapy Revenue Market Share by Application (2020-2031)
Figure 22. North America Gene Editing Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Gene Editing Therapy Revenue (US$ Million) in 2024
Figure 24. North America Gene Editing Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Gene Editing Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Gene Editing Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Gene Editing Therapy Revenue (US$ Million) in 2024
Figure 31. Europe Gene Editing Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Gene Editing Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. France Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Gene Editing Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Gene Editing Therapy Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Gene Editing Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Gene Editing Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. India Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Gene Editing Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Gene Editing Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Gene Editing Therapy Revenue (US$ Million) in 2024
Figure 54. Central and South America Gene Editing Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Gene Editing Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Gene Editing Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Gene Editing Therapy Revenue (US$ Million) in 2024
Figure 60. South America Gene Editing Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Gene Editing Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Gene Editing Therapy Revenue (2020-2025) & (US$ Million)
Figure 66. Gene Editing Therapy Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
